Mediator kinase inhibition exposes a transcriptional vulnerability and synergizes with venetoclax in AML.
Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy associated with poor survival despite recent therapeutic advances. To identify novel anti-leukemic agents, we performed a high-throughput viability screen of 10,000 small molecules across 56 genetically diverse primary AML samples. Co...